Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2586645 | 0.78 | TP53 (0.52) | KMT2AMEN1CNR1HTTMAPT | |
| SCHEMBL4264818 | 0.78 | ALDH1A1 (0.48) | KMT2AMEN1CNR1NPSR1HTT | |
| SCHEMBL2588302 | 0.77 | USP2 (0.41) | KMT2AMEN1CNR1NPSR1HTT | |
| SCHEMBL2586737 | 0.75 | TP53 (0.55) | MAPTTP53LMNA | |
| SCHEMBL2584833 | 0.74 | NPC1 (0.44) | KMT2AMEN1HTTMAPTTP53 | |
| SCHEMBL2588879 | 0.73 | HSP90AA1 (0.42) | KMT2AMEN1NPSR1HTTKDM4E | |
| SCHEMBL13548617 | 0.73 | CNR2 (0.52) | KMT2AMEN1CNR1NPSR1HTT | |
| SCHEMBL2581935 | 0.72 | L3MBTL1 (0.42) | KMT2AMEN1CNR1MAPTTP53 | |
| SCHEMBL13548548 | 0.72 | CYP2C9 (0.48) | KMT2AMEN1CNR1NPSR1HTT | |
| SCHEMBL2585772 | 0.71 | TDP1 (0.41) | KMT2AMEN1CNR1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869053-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-ISOXAZOLO[4,5-C]PYRIDINE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-10-09 | — | — | EP | claimed |
| US-8048879-B2 | Substituted 4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine compounds and use thereof for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | claimed |
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | claimed |
| EP-1869053-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-ISOXAZOLO[4,5-C]PYRIDINE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-8048879-B2 | Substituted 4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine compounds and use thereof for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | P2RX5, P2RX4, P2RX7 | KMT2A 4073/4885MEN1 2795/4885CNR1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.